PITX2 and ovarian neoplasm: On the other hand, the knockdown of one of these RGS proteins in ovarian tumor cells is responsible for a 2 to 3-fold decrease in the cisplatin potency while the knockdown of both RGS proteins leads to a 6-fold reduction of drug potency.